Navigation Links
Abingworth Appoints David Mayer as Partner
Date:4/29/2008

LONDON and BOSTON, April 29 /PRNewswire/ -- Abingworth, the international life sciences investment group, today announced the appointment of David Mayer as Partner. He will be based at the Company's offices in Waltham, MA, USA and his prime responsibility will be to support Abingworth's efforts in growth equity, which will include expansion and acquisition financings, small buyouts and build-ups in healthcare and life science companies. Abingworth plans to invest from 10 million pounds Sterling ($20 million) to up to 40 million pounds ($80 million) in each of its growth equity investments.

Mr. Mayer adds significant depth and expertise to Abingworth with more than 12 years experience in growth equity/buyouts, of which 8 years have been spent focused on the healthcare sector. Mr. Mayer was most recently a Managing Partner at Thoma Cressey Equity Partners (TCEP). He was one of five Managing Partners at TCEP, which managed more than $1.75 billion in capital, and he opened their Boston office in 2004. He was also responsible for expanding the areas within healthcare in which the firm now invests to include pharmaceuticals and medical products, in addition to healthcare services. Notable investments made during his time at TCEP include: ESP Pharma, Inc., Jazz Pharmaceuticals, Inc., Critical Care Systems, Inc., Essent Healthcare, Inc. and Continuing Care RX, Inc.

"We are delighted to welcome Dave to our investment team," said Stephen Bunting, Managing Partner of Abingworth. "He has a proven track record in growth equity and has served on the boards of several healthcare and life science companies. His broad network of contacts and extensive experience will provide valuable strategic support to our investment process and to our portfolio companies. We believe he is an excellent fit with our organization."

David Mayer said, "I am very pleased to be joining Abingworth, one of the pioneering investment firms in the life sciences area, and I look forward to being able to contribute my experience to help identify and develop growth equity opportunities for the firm."

About Abingworth

Abingworth is an international life sciences investment group active on both sides of the Atlantic with offices in London, Menlo Park (California) and Boston. Founded in 1973, the Company invests across all stages of development, including early-stage, growth equity and quoted companies in the healthcare and life sciences sectors. Abingworth has funds under management of over $1.25 billion.


'/>"/>
SOURCE Abingworth
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MIGENIX Appoints Pieter Dorsman to Board of Directors
2. Anavex appoints Dr. Dimitri Goundis to lead Clinical Development
3. Phytomedics Inc. Appoints Dr. Laurie Smaldone Alsup, MD., as President and Chief Executive Officer
4. Metabolex Appoints Donald Hill as Chief Financial Officer
5. Biopure Appoints New Independent Auditor
6. Indivumed Appoints Annette Kassen as Vice President Clinical Research
7. ADVENTRX Appoints Vice President of Manufacturing
8. Egenix, Inc. Appoints Dr. Daniel Petrylak Chairman of Scientific Advisory Board
9. NanoLogix Inc. Provides Financial Update, Appoints Bert Pharis as New Director
10. Observant LLC Appoints Two New Directors to the Senior Management Team
11. Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of ... health care systems, in terms of costs and resources. However, ... the development of innovative and efficient therapies that demonstrate higher ... types of cancer treatments, a growing number of patients receiving ...
(Date:3/22/2017)... 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today ... (RGC), U.K. Biobank and GSK to generate genetic sequence data ... The initiative will enable researchers to gain valuable insights to ... wide range of serious and life threatening diseases. ... Genetic evidence ...
(Date:3/22/2017)... , March 22, 2017 Oramed ... ( www.oramed.com ), a ... oral drug delivery systems, announced today that Dr. ... will deliver a presentation titled, "Oral Insulin for ... Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics (OPT) ...
(Date:3/22/2017)... CAMBRIDGE, Mass. , March 22, 2017   ... of next-generation cancer therapeutics designed to target cancer stemness ... Patricia S. Andrews as Chief Executive Officer, ... will succeed Chiang J. Li , M.D., FACP, ... company ten years ago. Under his leadership, Boston Biomedical ...
Breaking Biology Technology:
(Date:3/20/2017)... , March 20, 2017 PMD Healthcare announces ... spirometer and Wellness Management System (WMS), a remote, real-time ... in 2010, PMD Healthcare is a Medical Device, Digital ... mission dedicated to creating innovative solutions that empower people ... that intent focus, PMD developed the first ever personal ...
(Date:3/9/2017)... and MOUNTAIN VIEW, Calif. , ... Well Made Simple," and 23andMe , the leading ... better food choices.  Zipongo can now provide customers with ... preferences, health goals and biometrics, but also genetic markers ... choices. Zipongo,s personalized food decision support platform ...
(Date:3/2/2017)... Summary This report provides all the ... interests and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ...
Breaking Biology News(10 mins):